Loading...
Market
What market share will Dordaviprone capture in first year post-approval?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports and Chimerix financial disclosures
Story
Chimerix Submits Dordaviprone NDA for Accelerated Approval to U.S. FDA for Recurrent H3 K27M-Mutant Diffuse Glioma, Secures $30 Million Funding
Dec 30, 2024, 12:02 PM
Chimerix, Inc. has submitted a New Drug Application (NDA) for accelerated approval of its drug, Dordaviprone, to the U.S. Food and Drug Administration (FDA). The application targets patients with recurrent H3 K27M-mutant diffuse glioma, a type of brain cancer. In addition, Chimerix has entered into a credit facility of up to $30 million with Silicon Valley Bank. This funding aims to provide access to additional capital during the upcoming investment cycle and to ensure the availability of Dordaviprone to as many patients as possible, should it receive approval.
View original story
Similar markets
Negative results • 33%
Positive results • 33%
Inconclusive results • 34%
Increase by <5% • 25%
Increase by >10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Rejected • 25%
Decision delayed • 25%
Approved with conditions • 25%
Approved • 25%
Above $300 million • 25%
$200 million to $300 million • 25%
$100 million to $200 million • 25%
Below $100 million • 25%
Request for more data • 34%
Rejected • 33%
Approved • 33%
5% to 10% • 25%
Less than 5% • 25%
More than 20% • 25%
10% to 20% • 25%
20% to 30% • 25%
10% to 20% • 25%
More than 30% • 25%
Less than 10% • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%